Nyxoah 2023 Investor Presentation OSA Treatment

Nyxoah SA presents its obstructive sleep apnea (OSA) treatment platform using hypoglossal nerve stimulation (HGNS) technology. The company highlights a €111 million cash position post-IPO, CE Mark approval for European sales, and ongoing US regulatory pathways including the DREAM and ACCESS IDE trials. With 425 million eligible OSA patients globally, Nyxoah's innovative single-incision procedure targets a significant underpenetrated market.